Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'

AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data

Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.

Billionaire hedge fund manager Ken Griffin's Citadel increased its stake in AbbVie by 547% in Q2, adding 2.7 million shares worth approximately $798 million. The move reflects a defensive investment strategy into a stable dividend stock. AbbVie, a Dividend King with 54 consecutive years of dividend increases, currently yields 2.6% and has 75% of Wall Street analysts rating it as a buy with a median price target of $282.50.

Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.

Billionaire hedge fund manager Ken Griffin recently increased his stakes in AbbVie and Abbott Laboratories through his fund Citadel. The article analyzes whether retail investors should follow his lead, highlighting AbbVie's transition from Humira to new immunology drugs like Skyrizi and Rinvoq with expansion into oncology, and Abbott's strong positions in diabetes care, diagnostics, and medical devices. The author suggests both stocks merit consideration as part of a long-term healthcare allocation based on their business fundamentals rather than simply following Griffin's moves.

AbbVie To Present New Data From Its ABBV-1480 PD-1/VEGF Bispecific Antibody In Frontline Non-Small Cell Lung Cancer At 2026 World Conference On Lung Cancer

AbbVie (NYSE:ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer

Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?

The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.